je.st
news
Gilead's HCV Sales May Have Peaked
2015-11-30 16:10:15| Biotech - Topix.net
A potential rate hike and a disappointing Q4 earnings season could cause a pullback in broader markets, taking GILD with it. Gilead has been a tremendous growth story ever since its HCV drug, Sovaldi/Harvoni, hit the market.
Tags: sales
peaked
hcv
gileads
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||